AU689206B2 - Enantiomerically pure (+)-liarozole - Google Patents

Enantiomerically pure (+)-liarozole Download PDF

Info

Publication number
AU689206B2
AU689206B2 AU15787/95A AU1578795A AU689206B2 AU 689206 B2 AU689206 B2 AU 689206B2 AU 15787/95 A AU15787/95 A AU 15787/95A AU 1578795 A AU1578795 A AU 1578795A AU 689206 B2 AU689206 B2 AU 689206B2
Authority
AU
Australia
Prior art keywords
compound
acid
document
formula
international
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU15787/95A
Other languages
English (en)
Other versions
AU1578795A (en
Inventor
Marc Gaston Venet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU1578795A publication Critical patent/AU1578795A/en
Application granted granted Critical
Publication of AU689206B2 publication Critical patent/AU689206B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU15787/95A 1994-02-18 1995-02-10 Enantiomerically pure (+)-liarozole Expired - Fee Related AU689206B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94200420 1994-02-18
EP94200420 1994-02-18
PCT/EP1995/000490 WO1995022540A1 (en) 1994-02-18 1995-02-10 Enantiomerically pure (+)-liarozole

Publications (2)

Publication Number Publication Date
AU1578795A AU1578795A (en) 1995-09-04
AU689206B2 true AU689206B2 (en) 1998-03-26

Family

ID=8216652

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15787/95A Expired - Fee Related AU689206B2 (en) 1994-02-18 1995-02-10 Enantiomerically pure (+)-liarozole

Country Status (12)

Country Link
EP (1) EP0745077A1 (de)
JP (1) JPH09508914A (de)
CN (1) CN1141042A (de)
AU (1) AU689206B2 (de)
CA (1) CA2182583A1 (de)
IL (1) IL112688A0 (de)
MX (1) MX9603316A (de)
NZ (1) NZ279227A (de)
SG (1) SG52325A1 (de)
TW (1) TW401415B (de)
WO (1) WO1995022540A1 (de)
ZA (1) ZA951343B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800391A1 (de) * 1994-12-28 1997-10-15 Janssen Pharmaceutica N.V. Benzimidazole zur hemmung des calcitriol-metabolismus
EP1992228A1 (de) * 2007-05-14 2008-11-19 Bayer CropScience AG Insektizide substituierte Thiourea-Derivate
US9138393B2 (en) * 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) * 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260744A2 (de) * 1986-09-15 1988-03-23 Janssen Pharmaceutica N.V. (1H-Imidazol-1-ylmethyl) substituierte Benzimidazol-Derivate
EP0371559A2 (de) * 1988-11-29 1990-06-06 Janssen Pharmaceutica N.V. Verwendung von Benzimidazol-Derivaten bei der Behandlung von epithelialen Erkrankungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260744A2 (de) * 1986-09-15 1988-03-23 Janssen Pharmaceutica N.V. (1H-Imidazol-1-ylmethyl) substituierte Benzimidazol-Derivate
EP0371559A2 (de) * 1988-11-29 1990-06-06 Janssen Pharmaceutica N.V. Verwendung von Benzimidazol-Derivaten bei der Behandlung von epithelialen Erkrankungen

Also Published As

Publication number Publication date
IL112688A0 (en) 1995-05-26
MX9603316A (es) 1997-02-28
ZA951343B (en) 1996-08-19
TW401415B (en) 2000-08-11
WO1995022540A1 (en) 1995-08-24
CA2182583A1 (en) 1995-08-24
EP0745077A1 (de) 1996-12-04
CN1141042A (zh) 1997-01-22
JPH09508914A (ja) 1997-09-09
NZ279227A (en) 1997-11-24
SG52325A1 (en) 1998-09-28
AU1578795A (en) 1995-09-04

Similar Documents

Publication Publication Date Title
JP3404749B2 (ja) Ｎ―［４―（ヘテロアリールメチル）フェニル］―ヘテロアリールアミン
TWI293952B (en) Pyrazole derivatives, compositions containing such compounds and methods of use
EP0497659B1 (de) Aryl(oder Heteroaryl)-piperazinyl-alkyl-azol-derivate, ihre Herstellung und ihre Anwendung als Medikament
DE69626862T2 (de) Imidazolderivate mit alpha2-rezeptor aktivität
US5037829A (en) (1H-azol-1-ylmethyl) substituted quinazoline derivatives
KR19990007941A (ko) 벤즈이미다졸 화합물 및 감마-아미노부틸산 수용체 착물의 조절자로 그들의 용도
DK175793B1 (da) Substituerede benzimidazoler, deres fremstilling samt anvendelse til fremstilling af lægemidler mod epitellidelser
US5128343A (en) Derivatives of pyrimidinyl-piperazinyl-alkyl azoles with anxiolytic and/or tranquilizing activity
AU689206B2 (en) Enantiomerically pure (+)-liarozole
JPS63238070A (ja) 複素環式化合物、その製造法及びこの化合物を含有しアロマターゼ抑制効果を有する製薬又は獣医薬組成物
WO1999040062A1 (en) Hydrazone derivatives
EP0800524B1 (de) 6-[triazolyl[3-(trifluoromethyl)phenyl]methyl]-2-chinolinone und - chinolinonethione
US5254553A (en) 4-[4- [4-(4-hydroxyphenyl)-1-piperazinyl]phenyl]-5-methyl-3H-1,2,4-triazol-3-one derivatives
AU688852B2 (en) Enantiomerically pure(-)-liarozole
EP3932490A1 (de) Antipruritisches mittel unter verwendung von pac1-rezeptorantagonisten
EP0679647A1 (de) Neue Triazol-Verbindung mit fungizider Wirkung, deren Herstellung und Verwendung
US5441954A (en) (1h-azol-1-ylmethyl) substituted quinoline derivatives
US3864359A (en) 5-amino-3-ethyl-1-phenyl-4-pyrazolecarboxamides and method of preparation thereof
MXPA97004667A (en) 6- [triazolil [3-trifluoromethyl) phenyl] methyl] -2-quinolinones and quinolinotium
US20060041001A1 (en) Novel imidazolic compounds, method for preparing same and use thereif as medicines
CA2182581A1 (en) Enantiomerically pure(-)-liarozole
JPH06128239A (ja) 新規トリアゾール化合物及び該化合物を有効成分とする抗真菌剤
JPH07316140A (ja) 新規トリアゾール化合物及びその製法並びにその用途
NZ270798A (en) 1-(1,2,4-triazolyl)-3-methyl-2-phenyl-4-mercapto (or heteroarylalkyl)butan-2-ol derivatives; antifungal medicaments
FR2462436A1 (fr) Nouvelles 2-(5-pyrazolylamino)-2-imidazolines, utiles notamment comme agents anti-inflammatoires, et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application